Working together for the family: determination of HER oncogene co-amplifications in breast cancer

• Published in: Oncotarget Vol. 11; no. 28; pp. 2774 - 2792
• Main Authors: Laurito, Sergio, Branham, María Teresita, Campoy, Emanuel, Real, Sebastián, Cueto, Juan, Urrutia, Guillermo, Gago, Francisco, Tello, Olga, Glatstein, Telma, De la Iglesia, Paola, Atanesyan, Lilit, Savola, Suvi, Roqué, Maria
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 14.07.2020
• Subjects: Research Paper; breast cancer; co-amplification; MLPA; digital PCR; HER oncogenes
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.27671

HER2 is a well-studied tyrosine kinase (TK) membrane receptor which functions as a therapeutic target in invasive ductal breast carcinomas (IDC). The standard of care for the treatment of HER2-positive breast is the antibody trastuzumab. Despite specific treatment unfortunately, 20% of primary and 70% of metastatic HER2 tumors develop resistance. HER2 belongs to a gene family, with four members (HER1-4) and these members could be involved in resistance to anti-HER2 therapies. In this study we designed a probemix to detect the amplification of the four HER oncogenes in a single reaction. In addition, we developed a protocol based on the combination of MLPA with ddPCR to detect the tumor proportion of co-amplified HERs. On 111 IDC, the HER2 MLPA results were validated by FISH (Adjusted = 0,91, < 0,0001), CISH (Adjusted = 0,938, < 0,0001) and IHC (Adjusted = 0,31, < 0,0001). HER1-4 MLPA results were validated by RT-qPCR assays (Spearman Rank test < 0,05). Of the 111 samples, 26% presented at least one HER amplified, of which 23% showed co-amplifications with other HERs. The percentage of cells with HER2 varied among the tumors (from 2-72,6%). Independent findings show that the outcome of HER2+ patients is conditioned by the status of HER3 and HER4. Our results encourage further studies to investigate the relationship with patient's response to single or combined treatment. The approach could serve as proof of principle for other tumors in which the HER oncogenes are involved.